The company’s stock has a 5-day price change of -3.39% and -52.42% over the past three months. BDRX shares are trading -29.63% year to date (YTD), with the 12-month market performance down to -91.16% lower. It has a 12-month low price of $2.78 and touched a high of $74.00 over the same period. BDRX has an average intraday trading volume of 441.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.36%, -30.21%, and -74.08% respectively.
Institutional ownership of Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) shares accounts for 1.27% of the company’s 0.36M shares outstanding.
It has a market capitalization of $1.65M and a beta (3y monthly) value of 1.49. The earnings-per-share (ttm) stands at -$49.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.04% over the week and 18.53% over the month.
Analysts forecast that Biodexa Pharmaceuticals Plc ADR (BDRX) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and -0.05 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 99.87%, and 12.18% over the next financial year. EPS should grow at an annualized rate of 89.98% over the next five years, compared to 86.34% over the past 5-year period.
Looking at the support for the BDRX, a number of firms have released research notes about the stock. Ladenburg Thalmann stated their Buy rating for the stock in a research note on February 08, 2024, with the firm’s price target at $8.
